Idexx Laboratories Inc /De reports $1.21 billion revenue for quarter ended September 30, 2026, up 9.9%
Idexx Laboratories Inc /De reported revenue of $1.21 billion for the quarter ended September 30, 2026, an increase of 9.9% from the same quarter a year earlier ($1.11 billion).
For the same period it posted net income of $317.1 million, up 15.5%, or $4.01 per diluted share (3.40 a year earlier).
That is a net margin of 26.1%.
On Sanad's AAOIFI Standard 21 screen, Idexx Laboratories Inc /De is currently compliant: interest-bearing debt is 0.7% of market capitalisation (limit 30%), and impure income is 0.1% of revenue (limit 5%).
Is Idexx Laboratories Inc /De halal?
See the full AAOIFI screening of Idexx Laboratories Inc /De
See the full AAOIFI screening of Idexx Laboratories Inc /De
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 2, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.